CHAPTER 5 Brendan Tinwell and Ian Hunt St George’s Hospital, London, UK The lungs are invested by a thin serous membrane, the visceral pleura, which is reflected on to the chest wall at the hilum of each lung to form the parietal pleura, which is also reflected on to the mediastinum and diaphragm. The parietal pleura extends superiorly into the root of the neck (approximately 3 cm above the midpoint of the clavicle) and inferiorly into the costodiaphragmatic recesses at the level of the 12th rib (overlying the kidney). The visceral pleura further extends into the lung as major fissures, dividing the lungs into lobes, and can be regarded as consisting of three layers: The pathological processes involving the pleura may be conveniently classified into neoplastic and non‐neoplastic, the latter including inflammatory and tumour‐like conditions. Primary diseases of the pleura of any type are rare (e.g. solitary fibrous tumour or malignant mesothelioma), and the pleura is usually involved secondarily by disease processes located elsewhere (e.g. bacterial pneumonia leading to empyema, or lung carcinoma with metastases to the pleura). Pleural effusion (accumulation of fluid in the pleural space) is a common manifestation of many of these primary and secondary pleural disorders and most are related to infections, malignancy, heart failure or pulmonary emboli. Normally, there is less than 1 mL of fluid within the pleural cavity, this being maintained by a balance between hydrostatic and oncotic pressure within parietal and visceral pleural vessels, and by an extensive network of lymphatic channels which drain fluid away. Inflammatory disorders result in increased vascular permeability and therefore leakage of protein‐rich serous or haemorrhagic exudate into the pleural cavity causing an exudative pleural effusion. Similarly, malignancies cause vascular alterations and obstruction of lymphatics resulting in an exudate forming within the pleural space. A non‐inflammatory or transudative pleural effusion, also referred to as hydrothorax, is typically bilateral, low in protein and usually results from increased capillary hydrostatic pressure (such as in heart failure) or reduced colloid osmotic pressure (such as in hypo‐albuminaemia caused by cirrhosis or nephrotic syndrome). Measurement of pH, glucose, protein and lactate dehydrogenase (LDH) concentrations in pleural fluid and blood may aid the distinction between exudates and transudates, but more specialised pleural fluid assays (e.g. natriuretic peptides in heart failure or chylomicrons in chylothorax) may be employed in certain cases. Chylothorax (or chylous pleural effusion) is a special type of effusion (usually exudative) referring to accumulation of lymphocytes, immunoglobulin and lipid‐rich milky fluid in the pleural cavity. Chylothorax may be secondary to traumatic rupture of major lymphatic ducts or obstruction thereof by tumour, most of which are malignant lymphomas. The chylous fluid forms a creamy or fatty supernatant when left to stand and contains a high concentration of chylomicrons and triglyceride (although the latter may be low). Pseudochylothorax is caused by cholesterol crystal accumulation in any chronic pleural effusion (especially those related to tuberculosis, rheumatoid disease or chronic haemothorax) and is usually neutrophil‐rich and lacking chylomicrons. Urinothorax is a rare cause of pleural effusion which may be considered in patients with undiagnosed pleural effusion associated with obstructive uropathy, urological trauma (including surgical injury) or kidney biopsy. Of neoplasms involving the pleura, metastatic cancers are much more common than primary pleural tumours, greatly outnumbering the most common and most important of these, diffuse malignant mesothelioma. In the USA, for example, there are approximately 130 cases of metastatic tumour to the pleura for each case of diffuse malignant mesothelioma of the pleura. It is worth noting here that lung cancer is one of the most common tumours to metastasise to the pleura, and that there has recently been a reclassification of the American Joint Committee on Cancer (AJCC) TNM staging of lung cancer (7th edition) to reflect the fact that lung cancer patients with pleural metastases – either pleural nodules or malignant effusion, demonstrate similar survival as patients with contralateral lung nodules (both M1a) and that patients with distant visceral metastases (M1b) have significantly worse survival. Benign and malignant tumours of the pleura are listed in Table 5.1. Table 5.1 Classification of benign and malignant neoplasms of the pleura, including tumour‐like conditions. PNET, primitive neuroectodermal tumour. Solitary fibrous tumour (SFT) is the second most common primary pleural neoplasm (and the most common benign primary pleural tumour) but is far outnumbered by diffuse malignant mesothelioma of the pleura, such that SFT accounts for <5% of all primary pleural tumours. This tumour is more frequently encountered in extrapleural sites including the head and neck region, retroperitoneum, soft tissues, liver, breast, and so on and pleural tumours were previously erroneously referred to as ‘localised fibrous mesothelioma’. SFT of the pleura is thought to arise from fibroblast‐like, submesothelial mesenchymal cells and affects individuals of both sexes over a wide age range (usually sixth decade), where up to 25% present with an incidental, pleural‐based mass on a chest radiograph performed for other reasons. It is benign, slow‐growing and not associated with asbestos exposure. Patients with malignant SFT (one‐third of cases) are more likely to present with cough, chest pain, dyspnoea or pleural effusion. Two unusual clinical syndromes are encountered with SFT:
Pleural Pathology
Normal anatomy and histology of the pleura
Pathological processes involving the pleura
Benign neoplasms
Primary malignant neoplasms (other than mesothelioma)
Solitary fibrous tumour
Adenomatoid tumour
Calcifying fibrous pseudotumour
Lipoma
Lipoblastoma
Schwannoma
Neurofibroma
Malignant solitary fibrous tumour
Pleuropulmonary blastoma
Synovial sarcoma
Angiosarcoma
Epithelioid haemangioendothelioma
Primary effusion lymphoma
Pyothorax‐associated lymphoma
Ewing sarcoma/PNET (Askin tumour)
Desmoplastic small round cell tumour
Pleural liposarcoma
Pleural thymoma (low malignant potential)
Pleural desmoid tumour (low malignant potential)
Pleural Rosai–Dorfman disease
Tumour‐like conditions
Secondary malignant neoplasms
Reactive eosinophilic pleuritis
Nodular pleural plaque
Amyloid deposition
Pleuropulmonary endometriosis
Metastatic carcinoma (especially lung, breast, gastrointestinal tract, ovary and kidney)
Malignant lymphoma
Metastatic malignant melanoma
Metastatic sarcoma
Neoplasia (other than diffuse malignant mesothelioma) – primary pleural neoplasms and tumour‐like proliferations
Benign
Solitary fibrous tumour